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A pilot study of EVAP/ABV chemotherapy in 25 newly diagnosed
children with Hodgkin's disease
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Australian and New Zealand Children's Cancer Study Group, Royal Children's Hospital, Melbourne, Australia.
Summary Twenty five children with newly diagnosed Hodgkin's disease were clinically staged and treated
with a chemotherapy protocol designed to reduce delayed toxicity. Four patients without macroscopic residual
disease after biopsy received three cycles of hybrid EVAP/ABV. All remain in CR 31-46 months from
diagnosis. One other developed fever and rash considered to be due to Ara-C and was treated with MOPP.
Twenty patients had macroscopic residual disease after biopsy and were treated with two cycles of EVAP
alone and reassessed with imaging and gallium scans. Twelve achieved CR, seven PR and one was not
evaluable. Patients in CR were subsequently treated with 2-4 cycles of hybrid EVAP/ABV, while those in PR
received 3-4 cycles. At a median follow up of 37 months the overall survival was 100%, relapse free 79% and
treatment failure free 60%. Eight patients had mediastinal widening >J thoracic width. At the completion of
the protocol five achieved CR, two PR and one was withdrawn from study at investigator preference. One
patient has subsequently relapsed. Of the evaluable ten patients without a mediastinal presentation all achieved
CR but three relapsed at 10, 13 and 18 months from diagnosis. Patients who achieved a PR only, relapsed or
were withdrawn from study have been salvaged with MOPP or ChlVPP chemotherapy.
In childhood, there is growing evidence that all stages of
Hodgkin's disease can be successfully treated with combina-
tion chemotherapy such as MOPP (Ekert & Waters, 1983;
Ekert et al., 1988) (mechlorethamine, oncovin, prednisone,
procarbazine) or ChlVPP (Robinson et al., 1984) (chloram-
bucil, vinblastine, prednisone, procarbazine) without irradia-
tion. Irradiation in the treatment of early stage disease has
been eliminated from these protocols because in the long
term it causes growth retardation and its use as the only
modality of treatment requires staging laparotomy and
splenectomy in the majority of patients. Combined modality
treatment has also been avoided because of concern with
cumulative toxicity, including immunosuppression and sec-
ond cancers (Meadows et al., 1989). However, it is now well
established that there are important long term toxicities of
MOPP and ChlVPP of which the most serious are develop-
ment of acute non-lymphocytic leukaemia (Meadows et al.,
1989) and infertility in males of all ages (Aubier et al., 1989).
In an attempt to reduce the toxicity of treatment the
Australian and New Zealand Children's Cancer Study Group
(ANZCCSG) has piloted a potentially less toxic regimen
utilising etoposide, vinblastine, Ara-C and cis-
diaminodichloro-platinum (EVAP) (Wimmer et al., 1987;
Rybak et al., 1990; Longo, 1990) as induction chemotherapy,
followed by alternating courses of EVAP and doxorubicin
hydrochloride (dox), vincristine, bleomycin (ABV). The use
of etoposide and cis-diaminodichloro-platinum in the EVAP
regimen was based on response rates of approximately 20%
to etoposide and cis-diaminodichloro-platinum as single
agents (O'Dwyer et al., 1985; O'Reilly et al., 1991; Corder et
al., 1979;, Rossoff et al., 1979; Cavilli, 1982). Ara-C was
chosen because of its documented role in the treatment of
non Hodgkins lymphoma and its previous use in the 'APE'
combination chemotherapy regimen (Wimmer et al., 1987)
(cytosine arabinoside, cisplatin, etoposide).
We now report the results of the use of this chemotherapy
regimen in 25 newly diagnosed children with all stages of
Hodgkin's disease followed for a median of 37 months.
Patients and methods
Informed consent was obtained from all families and patients
participating in the study. They were told that there were
three main methods of treatment. One used irradiation and
staging laparotomy for early stage disease or MOPP and
irradiation for all stages. The second was MOPP chemo-
therapy alone while the third was the experimental protocol.
The side effects of each modality of therapy were outlined.
The patients and their family were told that relapses could be
salvaged with MOPP and/or irradiation. All patients with
biopsy proven Hodgkin's disease were eligible and all agreed
to participate. At the time ofbiopsy, surgeons were requested
not to attempt complete clearance of involved lymph nodes.
Staging was clinical, using the Ann Arbor classification (Car-
bone et al., 1971). All patients were further staged with chest
and abdominal CT scans, double dose gallium scans and
bone marrow trephines. Lymphography was not undertaken.
In Table I are shown, the age, sex, histology and clinical
stage of the patients entered into the study.
The chemotherapy regimen is summarised in Figure 1. In
patients with measurable residual disease after biopsy, it
consisted of vinblastine 4 mg m-2, Ara-C 3 Gm m-2, eto-
poside 120 mg m-2 and cis-platin 40 mg m-2, given on days 1
and 8 and repeated on days 29 and 36. Response to EVAP
was assessed with chest or abdominal CT scans and double
dose gallium scan, 3 weeks after completion of EVAP. The
same imaging and nuclear medicine investigations were again
repeated 3-4 weeks after completion of the full protocol.
In patients without measurable residual disease, vinblas-
tine, Ara-C, etoposide and cisplatin were given on day 1 and
vincristine 1.5 mg m-2, dox 25 mg m-2 and bleomycin 10 mg
m 2 on day 8. Three of these hybrid cycles of chemotherapy
were given at 4 week intervals. Response to treatment was
assessed with gallium scan 3 weeks after completion of
therapy.
All patients with residual disease who achieved complete
remission (CR) after two cycles of EVAP were given a fur-
ther two cycles of hybrid EVAP/ABV for those with non-
mediastinal presentation and four cycles for those with a
mediastinal presentation and re-assessed as before. Patients
with evidence of residual disease but no progression after two
cycles of EVAP (PR) were given three further cycles of
EVAP/ABV for non-mediastinal presentation and four for
mediastinal presentation and reassessed 3-4 weeks after
completion of chemotherapy. In assessing residual disease
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Table I Clinical features, staging and response to treatment
Response Time to
Sites ofPred. Clinical Response to end of treatment
Pt. Age Sex disease stage Hist. EVAP protocol failure (M) DFS (M)
No residual disease after biopsy
I 10 M Cervical IA LP NRD CR 36 + 36 +
2 3 M Cervical IA NS NRD CR 46+ 46+
3 5 M Cervical IA NS NRD NE 1 (allergy) 44+
4 13 M Cervical IA MC NRD CR 42 + 42 +
5 13 M Cervical IA NS NRD CR 31 + 31 +
Mediastinal enlargement
6 14 F Mediastinal/cervical IVA NS PR CR 34 + 34 +
7 14 F Mediastinal/abdominal IIIA NS PR PR 7 46 +
8 16 M Mediastinal/cervical IIIB NS PR PR 6 44 +
9 14 F Mediastinal/cervical IIA NS CR CR 32 + 32 +
10 4 M Mediastinal/cervical IIA MC CR CR 31 + 31 +
11 12 M Mediastinal IA NS CR CR 24 47 +
12 14 F Mediastinal/cervical IIA NS CR CR 24 + 24 +
13 13 M Mediastinal IA MC PR NE 3 (*) 24 +
Non-mediastinal lymph node involvement
14 10 M Abdominal IIB MC PR CR 35 + 35 +
15 7 M Cervical IA MC CR CR 44 + 44 +
16 16 F Cervical/abdominal IIIA NS CR CR 36 + 36 +
17 7 M Cervical IA LP CR CR 18 39 +
18 11 M Cervical IA NS CR CR 37 + 37 +
19 14 M Cervical IA NS PR CR 47 + 47 +
20 5 F Cervical IA LP CR CR 40+ 40+
21 8 F Cervical IIA LP CR CR 10 38 +
22 6 M Cervical IA MC PR CR 13 30 +
23 4 M Inguinal IIA NS CR CR 5 (*) 28 +
24 3 M Cervical IA NS NE NE - (anaph.) 19 +
25 14 M Cervical (lung) IVA NS CR CR 24+ 24+
N.S. nodular sclerosis; MC-mixed cellularity; LP-lymphocyte dominant; CR-complete remission; PR-partial remission
(>50% reduction of tumour size); NRD-no residual disease; NE-not available; M-month; DFS-disease free survival;
anaph-anaphylaxis; *-protocol violation.
after two cycles of EVAP mediastinal widening of any degree
by chest radiography and CT scans was considered to repre-
sent persistence of Hodgkin's disease. However, if at the
completion of treatment there was a decrease of mediastinal
widening, but not a return to normal the patients were
observed and only considered to have failed treatment if the
mediastinum continued to widen, there was increased gallium
uptake, or relapse at other sites.
Patients who had progressive disease after two cycles of
EVAP; failed to achieve remission at the completion of the
planned course of treatment; or who relapsed after treatment
were changed to MOPP or Ch1VPP and given at least three
cycles.
The results of this study were analysed according to the
recommendations of Dixon et al. (1987). The following end
points are reported:
(i) Survival
Percent of patients surviving from entry into study
until death or last known follow up time at least
April 1991 for all patients.
(ii) Treatment failure
Percent of patients who have failed to respond,
relapsed, died or were withdrawn for any reason
from the time of entry on the protocol.
(iii) Relapse
Percent who achieved remission and subsequently
relapsed at the completion of the full protocol of
treatment.
Results
The study commenced in June 1987 and ceased in June 1989.
The results were assessed in April 1991. The demographic
characteristics of all patients and the response to treatment
with EVAP only and after completion of EVAP/ABV are
shown in Table I.
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Figure 1 Treatment flow chart. EVAP consists of Etoposide
120mg m-2, V = vinblastine 4mgm-2, Ara-C 3 G m2 and cis-
platin 40mgm-2. ABV consists of dox 25 mgm-2, vincristine
1.5mgm-2 and bleomycin 10 mgm-2.
Patients with residual disease after biopsy
There were eight patients presenting with widening of the
mediastinum > i thoracic width. Their ages range from 4-16
years with a median of 14 and four were males. Clinical
staging showed that two had IA, three 3IIA, one III A, one
IIIB and one IVA disease.
There were 12 patients with non mediastinal presentation,
nine male and three female. Their ages ranged from 3-16
years with a median of 8. Stage IA disease was present in
seven, IIA in two, IIB in one, IIIA in one and IVA in one.
The main presenting feature was cervical node enlargement
in nine and inguinal in three.
At the completion of EVAP treatment four patients with
mediastinal enlargement achieved CR and four PR. In the
non mediastinal group one patient (No. 24) was withdrawn
after the first cycle of EVAP because of an anaphylacticEVAP/ABV CHEMOTHERAPY FOR HODGKIN'S DISEASE 161
reaction to etoposide. Of the remaining 11, eight achieved
CR and three PR after EVAP treatment. Thus of the 19
evaluable patients with residual disease after biopsy 12
achieved CR and seven PR. None had progressive disease.
At the completion of the protocol, of the eight patients
with mediastinal enlargement five achieved CR, two re-
mained in PR and one with PR (No. 13) was withdrawn
because of investigator preference for ChlVPP therapy. The
two patients with PR had significant mediastinal widening on
chest radiography and CT scans, but no increased gallium
uptake. They were observed for 8 weeks and reassessed with
radiography, chest CT and gallium scans. One, (No. 7) had
no further mediastinal widening but a positive gallium scan.
The other, (No. 8) had an increase in mediastinal widening
and a positive gallium scan. Both were treated with five
courses of MOPP and remain in remission at 44 and 46
months from diagnosis.
Of the 12 patients with non mediastinal presentation, but
with residual disease after biopsy 11 achieved CR at the
completion of the protocol. One was withdrawn because of
an anaphylactic reaction to etoposide after one cycle of
EVAP. He was treated with ChIVAPP and remains in remis-
sion 19 months from diagnosis. Another patient (No. 23)
achieved CR at the end of the protocol but his off treatment
response could not be followed because of parental insistence
that he be given an additional three courses of MOPP. He
remains in remission.
Relapse of disease occurred in four patients. One had
mediastinal disease (No. 11), achieved CR in response to
EVAP and remained in CR at the completion of the protocol
but relapsed at 24 months with Stage IVB disease. He was
treated with MOPP and remains disease free 47 months from
diagnosis.
Three patients with non mediastinal presentation (Nos. 17,
21, 22) subsequently relapsed at the site ofprevious disease at
10, 13 and 18 months from diagnosis. Two of these had
achieved CR with EVAP and one PR. All three achieved CR
with MOPP but one (No. 22) relapsed again and was treated
with ABVD induction followed by autologous bone marrow
transplantation with BCNU, Ara-C and Melphalan condi-
tioning.
Patients with no residual disease after diagnostic biopsy
There were five patients in this category, they were all males
and had Stage I cervical disease. One (No. 3) was withdrawn
1.00
0.75
from the protocol with rash and fever considered to be due
to Ara-C. He was treated with three cycles of MOPP and is
in remission 44 months from diagnosis. The remaining four
patients tolerated their treatment well and are in remission
31-46 months from diagnosis.
Overall results
Figure 2 shows that the overall survival is 100% with a
median follow up time of 37 months from diagnosis. Relapse
free survival coald only be assessed in 19 patients and was
79%. Six patients were not evaluable because four were
withdrawn from protocol and two failed to achieve CR.
Treatment failure free survival was assessed in all patients
and was 60%. It was 66% if the two patients withdrawn for
physician and patient preference are excluded as treatment
failures, but evaluated until the time of their withdrawal from
study.
Toxicity
The regimen was well tolerated with only moderate emesis
controllable with standard anti-emetics. Admissions to hos-
pital were required for hematologic toxicity and fever and
neutropenia following 15 of 132 EVAP courses. Of the 15
admissions platelet transfusions were required in three and
packed red cell transfusions in three patients. Allergic reac-
tions to etoposide and Ara-C each occurred in one patient.
All patients received chemotherapy at time intervals specified
in the protocol and none required dose reduction. There was
no evidence of impairment of renal function as measured by
serum creatinine levels but EDTA Cr clearances were not
performed. Routine audiology was not performed. Fertility
and cardiac function studies are planned for the future.
Discussion
This is the first report of hybrid EVAP/ABV chemotherapy
in newly diagnosed children with Hodgkin's disease. We
elected to pilot this protocol for two reasons. First, because it
may be potentially less toxic than MOPP, ChlVPP or
ABVD, as high doses of alkylating agents and anthracyclines
are avoided. This should reduce the incidence of infertility,
second malignancies and cardiomyopathy. Second, we
reasoned that because EVAP had been shown to be an
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effective remission induction combination in previously
treated patients with Hodgkin's disease (Wimmer et al., 1987;
Rybak et al., 1990; Longo et al., 1990) it should also be
effective in newly diagnosed patients. Furthermore, the use of
a hybrid EVAP/ABV combination permitted reduction of the
cumulative dose of anthracycline to a non-cardiotoxic dose
of no more than 100 mg m-2 and limited the dose ofcisplatin
to no more than 320 mgm-2. These dose levels of cisplatin
have only a low incidence of nephrotoxicity and hearing
disturbances. We considered the hybrid combination suffic-
iently intensive to eliminate DTIC from the ABVD regimen.
In order to assess the effectiveness of EVAP in remission
induction the protocol was constructed to allow investigation
of response to two cycles of EVAP alone. Our results showed
that two cycles of EVAP induced CR in 12 and PR in seven
of the 19 evaluable patients. (Five no evaluable disease after
biopsy, one anaphylactic reaction to etoposide). Four of the
seven patients in PR presented with major mediastinal
disease which at the time of reassessment had reduced in size,
but still showed mediastinal widening and reduced but persis-
tent' gallium uptake.
It is possible that these patients may have achieved CR
had the investigations been repeated some weeks later but we
did not consider this to be in the patient's best interest as it
would have meant a delay in subsequent chemotherapy.
The hybrid EVAP/ABV chemotherapy was effective in
eliminating microscopic disease in the four patients who had
no residual disease after biopsy and tolerated this regimen. It
was also effective in the seven patients who achieved PR at
the completion of two cycles of EVAP as only two failed to
achieve CR at the completion of the protocol. It is likely that
the ABV component of the hybrid protocol was of major
importance in these patients progress from PR to CR.
Unlike the results that we previously reported with MOPP
or ChlVPP (Ekert & Water, 1983; Ekert et al., 1988) there
was a significant incidence of relapse with four of 19
evaluable patients who achieved CR relapsing at sites of
previous disease. There was also a high incidence of treat-
ment failures. This was largely due to side effects of Ara-C
and etoposide and withdrawal of patients by investigators
despite the fact that the patients were in CR at the time of
withdrawal. These are not uncommon events in a pilot study
using an unconventional treatment regimen.
The purpose of this study was to pilot a potentially
effective and less toxic chemotherapy regimen. Our results
show that it was effective in achieving a lasting disease free
status in 60% of patients including four of eight with major
mediastinal disease. All patients who failed on the protocol
could be salvaged with more intensive chemotherapy, such as
MOPP. The duration of follow-up is still too short to be
certain that late relapses will not occur in these patients.
While the EVAP/ABV hybrid cannot be considered as an
optimum low intensity, potentially less toxic therapy for
newly diagnosed patients, it points the way for further pilot
studies by demonstrating partial effectiveness and the ability
to salvage at least in the short term chemotherapy failures
with alternate chemotherapy.
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